vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and SILICOM LTD. (SILC). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $61.9M, roughly 1.3× SILICOM LTD.). SILICOM LTD. runs the higher net margin — -18.5% vs -38.1%, a 19.5% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 6.6%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

Silicom Ltd. is a publicly traded company, headquartered in Israel, that specializes in the design, manufacture and marketing of connectivity solutions for a range of servers and server-based systems. Its shares are listed on the NASDAQ Global Market and on the Tel Aviv Stock Exchange. Silicom is a member of the RAD Group family of companies.

PRCT vs SILC — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.3× larger
PRCT
$83.1M
$61.9M
SILC
Growing faster (revenue YoY)
PRCT
PRCT
+13.6% gap
PRCT
20.2%
6.6%
SILC
Higher net margin
SILC
SILC
19.5% more per $
SILC
-18.5%
-38.1%
PRCT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCT
PRCT
SILC
SILC
Revenue
$83.1M
$61.9M
Net Profit
$-31.6M
$-11.5M
Gross Margin
64.9%
30.6%
Operating Margin
-4.1%
-19.8%
Net Margin
-38.1%
-18.5%
Revenue YoY
20.2%
6.6%
Net Profit YoY
-27.9%
16.3%
EPS (diluted)
$-0.56
$-2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
SILC
SILC
Q1 26
$83.1M
Q4 25
$76.4M
$61.9M
Q3 25
$83.3M
Q2 25
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
$58.1M
Q3 24
$58.4M
Q2 24
$53.4M
Net Profit
PRCT
PRCT
SILC
SILC
Q1 26
$-31.6M
Q4 25
$-29.8M
$-11.5M
Q3 25
$-21.4M
Q2 25
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
$-13.7M
Q3 24
$-21.0M
Q2 24
$-25.6M
Gross Margin
PRCT
PRCT
SILC
SILC
Q1 26
64.9%
Q4 25
60.6%
30.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
28.6%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
SILC
SILC
Q1 26
-4.1%
Q4 25
-40.6%
-19.8%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
-22.8%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
PRCT
PRCT
SILC
SILC
Q1 26
-38.1%
Q4 25
-39.1%
-18.5%
Q3 25
-25.7%
Q2 25
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
-23.6%
Q3 24
-35.9%
Q2 24
-48.0%
EPS (diluted)
PRCT
PRCT
SILC
SILC
Q1 26
$-0.56
Q4 25
$-0.54
$-2.01
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
$-2.28
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
SILC
SILC
Cash + ST InvestmentsLiquidity on hand
$245.6M
$42.1M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
$117.5M
Total Assets
$487.1M
$152.2M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
SILC
SILC
Q1 26
$245.6M
Q4 25
$286.5M
$42.1M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
$72.1M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
PRCT
PRCT
SILC
SILC
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
PRCT
PRCT
SILC
SILC
Q1 26
$347.7M
Q4 25
$365.9M
$117.5M
Q3 25
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
$127.8M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
PRCT
PRCT
SILC
SILC
Q1 26
$487.1M
Q4 25
$508.1M
$152.2M
Q3 25
$511.5M
Q2 25
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
$150.4M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
PRCT
PRCT
SILC
SILC
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
SILC
SILC
Operating Cash FlowLast quarter
$-2.2M
Free Cash FlowOCF − Capex
$-3.3M
FCF MarginFCF / Revenue
-5.4%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
SILC
SILC
Q1 26
Q4 25
$-10.3M
$-2.2M
Q3 25
$-6.6M
Q2 25
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
$18.3M
Q3 24
$-18.8M
Q2 24
$-15.7M
Free Cash Flow
PRCT
PRCT
SILC
SILC
Q1 26
Q4 25
$-12.2M
$-3.3M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
$17.4M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
PRCT
PRCT
SILC
SILC
Q1 26
Q4 25
-15.9%
-5.4%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
29.9%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
PRCT
PRCT
SILC
SILC
Q1 26
Q4 25
2.4%
1.9%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
1.6%
Q3 24
0.4%
Q2 24
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

SILC
SILC

Segment breakdown not available.

Related Comparisons